Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know

Gilead (GILD) wraps up $7.8B Arcellx deal, gaining anito-cel therapy. Stock tests key support at $128 with oversold RSI signaling potential reversal.

The post Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know appeared first on Blockonomi.